{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:40:58Z","timestamp":1790480458948,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Polycystic Kidney Disease Foundation","award":["1U18FD005320"],"award-info":[{"award-number":["1U18FD005320"]}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1053\/j.ajkd.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T17:45:22Z","timestamp":1546105522000},"page":"533-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)"],"prefix":"10.1053","volume":"73","author":[{"given":"Kimberly A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Broadbent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lundstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ajkd.2018.11.001_bib1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.01581105","article-title":"Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years","volume":"1","author":"Dicks","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2018.11.001_bib2","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD: Food and Drug Administration (US)","year":"2016"},{"issue":"12","key":"10.1053\/j.ajkd.2018.11.001_bib3","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo - the Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.001_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int"},{"issue":"24","key":"10.1053\/j.ajkd.2018.11.001_bib5","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2018.11.001_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","article-title":"Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study","volume":"63","author":"Miskulin","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2018.11.001_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.ajkd.2016.08.028","article-title":"Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial","volume":"69","author":"Casteleijn","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2018.11.001_bib8","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.001_bib9","first-page":"653","article-title":"Pathogenesis of hypertension in autosomal dominant polycystic kidney disease","volume":"11","author":"Chapman","year":"1991","journal-title":"Semin Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.001_bib10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/ki.1990.330","article-title":"Renal structure and hypertension in autosomal dominant polycystic kidney disease","volume":"38","author":"Gabow","year":"1990","journal-title":"Kidney Int"},{"issue":"16","key":"10.1053\/j.ajkd.2018.11.001_bib11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotension-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2018.11.001_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","article-title":"Liver involvement in early autosomal-dominant polycystic kidney disease","volume":"13","author":"Hogan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2018.11.001_bib13","author":"FDA"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.001_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","article-title":"Baseline total kidney\u00a0volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease","volume":"93","author":"Yu","year":"2018","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.001_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","article-title":"Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.001_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ekir.2017.02.011","article-title":"A\u00a0drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2018.11.001_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9147","key":"10.1053\/j.ajkd.2018.11.001_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.001_bib19","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1681\/ASN.2015060648","article-title":"Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease","volume":"27","author":"Hwang","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2018.11.001_bib20","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1681\/ASN.2015050583","article-title":"Predicted mutation strength of nontruncating PKD1 mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease","volume":"27","author":"Heyer","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.001_bib21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2018.11.001_bib22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.kint.2017.03.026","article-title":"Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease","volume":"92","author":"Kline","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2018.11.001_bib23","first-page":"1857","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial","volume":"32","author":"Irazabal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2018.11.001_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 Clinical Trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"20","key":"10.1053\/j.ajkd.2018.11.001_bib25","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.001_bib26","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1053\/j.ajkd.2014.09.006","article-title":"GFR decline as an end point in trials of CKD: a viewpoint from the FDA","volume":"64","author":"Thompson","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.001_bib27","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1053\/j.ajkd.2013.07.004","article-title":"Patient-reported outcomes in clinical trials of CKD-related therapies: report of a symposium sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"62","author":"Perrone","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2018.11.001_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","article-title":"Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument","volume":"71","author":"Oberdhan","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2018.11.001_bib29","article-title":"Guidance for industry","author":"FDA","year":"2017","journal-title":"Multiple endpoints in clinical trials"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.001_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and\u00a0functional\u00a0outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"10.1053\/j.ajkd.2018.11.001_bib31","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2018.11.001_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A\u00a0comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.001_bib33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1053\/j.ajkd.2005.08.026","article-title":"Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in\u00a0Polycystic Kidney Disease (CRISP)","volume":"46","author":"O\u2019Neill","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.001_bib34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2018.11.001_bib35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2018.11.001_bib36","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2018.11.001_bib37","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.001_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2018.11.001_bib39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2018.11.001_bib40","author":"FDA"},{"issue":"3","key":"10.1053\/j.ajkd.2018.11.001_bib41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00261-017-1236-y","article-title":"Quantitative MRI of kidneys in renal disease","volume":"43","author":"Kline","year":"2018","journal-title":"Abdom Radiol (NY)"},{"issue":"12","key":"10.1053\/j.ajkd.2018.11.001_bib42","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrneph.2017.127","article-title":"New treatment paradigms for ADPKD: moving towards precision medicine","volume":"13","author":"Lanktree","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2018.11.001_bib43","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2018.11.001_bib44","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1681\/ASN.2006080835","article-title":"Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease","volume":"17","author":"Harris","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2018.11.001_bib45","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfx188","article-title":"Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial","volume":"33","author":"Cornec-Le Gall","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2018.11.001_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/j.ajkd.2015.04.044","article-title":"Therapeutic area data standards for autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC)","volume":"66","author":"Perrone","year":"2015","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618310862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618310862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:20:51Z","timestamp":1759461651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638618310862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0272638618310862"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.11.001","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}